TwoStep Therapeutics secures $62.5M Series A to advance novel ADC approach
TwoStep Therapeutics, a cancer biotech, has raised $62.5 million in Series A funding from Pfizer and Merck KGaA's venture arms. The company is developing a distinct approach to antibody-drug conjugates and radioligands. The funds will support moving its lead program into clinical trials.
The financing round brings together two major pharmaceutical venture arms, signaling institutional confidence in the biotech's platform. This capital injection is earmarked specifically to transition the company's primary asset from preclinical development into human testing.
The company's research focuses on a novel variation of antibody-drug conjugates, alongside radioligand therapies. This dual focus aims to improve targeted delivery of cancer treatments, potentially offering a new avenue for oncological intervention as the lead program advances toward the clinic.
The successful financing could accelerate the development of next-generation cancer therapies, potentially expanding treatment options for patients with difficult-to-treat malignancies. If the distinct ADC and radioligand approach proves viable in clinical trials, it may offer more precise targeting, which could reduce systemic side effects compared to traditional chemotherapy. Additionally, this investment may encourage further venture capital interest in innovative oncology platforms, fostering a competitive landscape that could ultimately benefit patients and healthcare providers.